Sense Biodetection and Biotecom have entered an agreement for the non-exclusive distribution of the former’s Veros Covid-19 molecular testing platform in Chile.

The instrument-free Veros Covid-19 platform uses rapid molecular amplification technology and aims to improve access to quick, highly accurate, point-of-care testing.

It is claimed to be the first and only self-contained, single-use Covid-19 product that provides PCR-quality results in 15 minutes without the need for any external power supply or reader.

Veros helps to reduce the spread of Covid-19 through quick and precise diagnoses.

In a multicentre study, Veros Covid-19 was found to be easy to use, with all test site operators reporting that the device was easy to read and the results easy to understand, with less hands-on time.

Veros Covid-19 can detect all variants of interest and concern, including Omicron and its identified subvariants, currently identified by the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC).

Sense Biodetection chief commercial officer Ryan Roberts said: “This agreement is significant for Sense as it marks our entry into the South American markets.

“Together with Biotecom, we believe that by adding the instrument-free Veros Covid-19 to their portfolio, healthcare providers in Chile will be able to provide faster diagnosis and exceptional care for their patients right at the point of use by taking advantage of this rapid, laboratory-quality molecular test.”

Founded in 2013, Biotecom distributes quality molecular biotechnology products and reagents to national hospitals, clinics and laboratories in Chile.

In March, Sense Biodetection’s Veros Covid-19 molecular diagnostic test obtained CE Mark.